Chemotherapy induced nausea and vomiting (CINV) refers to the nausea and vomiting associated with cancer chemotherapy. Various sources indicate that approximately 70% to 80% cancer patients undergoing chemotherapy exhibit nausea and vomiting as major symptoms. Chemotherapy induced nausea and vomiting is an extremely debilitating condition. Although there are currently a number of drugs available to manage CINV, they do not effectively address the symptoms of this condition. The report on CINV existing and pipeline drugs market offers an insightful and in-depth assessment of the current as well as future market potential of CINV drugs. Aloxi (palonosetron), Zofran generic (ondansetron), Kytril generic (granisetron), Emend (aprepitant) and Akynzeo (netupitant-palonosetron FDC) are the major currently available drugs extensively studied in the report. The historical market size and forecast for each of these drugs (except for Akynzeo, as the U.S. Food and Drug Administration (FDA) approved it only in October 2014) in terms of revenue (USD Million) has been provided in the report for the period from 2012 to 2020. In addition, the compounded annual growth rate (CAGR) for each of these drugs has been provided in the report for the forecast period from 2014 to 2020, considering 2012 and 2013 as base years. The report also studies the CINV patient pool for each of these drugs. The market size and CAGR for Akynzeo have been determined for the years from 2015 to 2020.
The report also provides extensive analysis of the pipeline drugs SUSTOL (extended release granisetron injection) and rolapitant, including the status of current clinical trials and future sales projection in terms of USD million. The future sales projection of both these pipeline drugs has also been provided for the North American and European regions. The study also provides estimated patient pool for both these pipeline drugs, broken down by North America and Europe.
In this research study, the global market for CINV drugs has been geographically segmented into four regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). The CINV drugs market size and forecast in terms of revenue for each region has been provided for the period from 2012 to 2020 along with the CAGR for the forecast period from 2014 to 2020. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities. The market overview chapter provides information such as major subtypes of CINV, the etiology of CINV, the pathogenesis of CINV, major emetogenic chemotherapeutic agents, treatment recommendations for CINV and unmet needs in the CINV market. A section on event impact analysis has also been provided in the market overview chapter of the report on CINV existing and pipeline drugs market.
The report on chemotherapy induced nausea and vomiting drugs market also includes a section on the competitive landscape of the market, wherein the qualitative analysis of leading players in the global CINV drugs market is presented. The report concludes with the profiles of major players in the chemotherapy induced nausea and vomiting drugs market such as GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc. and Tesaro, Inc. Each company profile comprises information such as company overview, financial overview (selling, general and administrative expenses, research and development expenses and annual revenue for consecutive three years 2011, 2012 and 2013), current and pipeline product portfolio, business strategies and recent developments.
The global CINV existing and pipeline drugs market is segmented as follows:
CINV Existing and Pipeline Drugs Market Revenue (USD Million), by Major Drugs
- Aloxi (palonosetron)
- Zofran Generic (ondansetron)
- Kytril Generic (granisetron)
- Emend (aprepitant)
- Akynzeo (netupitant-palonosetron)
- SUSTOL (extended release granisetron injection)
CINV Existing and Pipeline Drugs Market Revenue (USD Million), by Geography
- North America
- Rest of the World (RoW)